Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) defied analyst predictions to release its quarterly results, which ...

George Tidmarsh, the newly installed director of the FDA’s Center for Drug Evaluation and Research, was placed on leave ...

Aurinia Pharmaceuticals (AUPH) could be a solid choice for investors given the company's remarkably improving earnings ...

The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...

The top drug regulator at the Food and Drug Administration (FDA) resigned Sunday, according to officials, after being accused ...

Reports suggest that, internally, the Food and Drug Administration is facing a crisis of confidence. Kennedy's reign has been ...

A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts and emails ...

Aurinia Pharmaceuticals (AUPH) stock slips as RBC Capital Markets downgrades the company following its better than expected ...

Aurinia Pharmaceuticals (AUPH) has swung into profitability over the past year, with earnings climbing at an impressive 43.8% per year on average for the past five years. Investors have watched as ...

Aurinia's Q3 2025 saw 27% LUPKYNIS sales growth and raised 2025 guidance. Discover key earnings insights, clinical updates, and pipeline progress.

Fintel reports that on November 7, 2025, Jefferies upgraded their outlook for Aurinia Pharmaceuticals (NasdaqGM:AUPH) from ...

Lupus nephritis (LN) is among the most severe and dangerous complications of systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease. LUPKYNIS is a calcineurin-inhibitor ...